Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition study

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB
[img]
Preview
PDF (Supporting Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Item Type:Article
Title:Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition study
Creators Name:Pham, T.T. and Nimptsch, K. and Aleksandrova, K. and Jenab, M. and Fedirko, V. and Wu, K. and Eriksen, A.K. and Tjønneland, A. and Severi, G. and Rothwell, J. and Kaaks, R. and Katzke, V. and Catalano, A. and Agnoli, C. and Masala, G. and De Magistris, M.S. and Tumino, R. and Vermeulen, R. and Aizpurua, A. and Trobajo-Sanmartín, C. and Chirlaque, M.D. and Sánchez, M.J. and Lu, S.S.M. and Cross, A.J. and Christakoudi, S. and Weiderpass, E. and Pischon, T.
Abstract:Resistin is a protein involved in inflammation and angiogenesis processes and may play a role in the progression of colorectal cancer (CRC). However, it remains unclear whether resistin is associated with increased mortality after CRC diagnosis. We examined pre-diagnostic serum resistin concentrations in relation to CRC-specific and all-cause mortality among 1343 incident CRC cases from the European Prospective Investigation into Cancer and Nutrition cohort. For CRC-specific mortality as the primary outcome, hazard ratios (HRs) and 95% confidence intervals (95% CI) were estimated from competing risk analyses based on cause-specific Cox proportional hazards models and further in sensitivity analyses using Fine–Gray proportional subdistribution hazards models. For all-cause mortality as the secondary outcome, Cox proportional hazards models were used. Subgroup analyses were performed by sex, tumor subsite, tumor stage, body mass index and time to CRC diagnosis. Resistin was measured on a median of 4.8 years before CRC diagnosis. During a median follow-up of 8.2 years, 474 deaths from CRC and 147 deaths from other causes were observed. Resistin concentrations were not associated with CRC-specific mortality (HR(Q4vsQ1) = 0.95, 95% CI: 0.73–1.23; P(trend) = .97; and HR(per doubling of resistin concentration) = 1.00; 95% CI: 0.84–1.19; P = .98) or all-cause mortality. Results from competing risk (sensitivity) analysis were similar. No associations were found in any subgroup analyses. These findings suggest no association between pre-diagnostic circulating resistin concentrations and CRC-specific or all-cause mortality among persons with CRC, and the potential insignificance of resistin in CRC progression.
Keywords:Colorectal Cancer, EPIC, Mortality, Pre-Diagnostic, Resistin, Survival
Source:International Journal of Cancer
ISSN:0020-7136
Publisher:Wiley
Volume:154
Number:9
Page Range:1596-1606
Date:1 May 2024
Official Publication:https://doi.org/10.1002/ijc.34830
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library